Drug Profile
Research programme: cannabinoid receptor CB2 modulatorsagonists - C4T SCarl
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator C4T SCarl
- Class
- Mechanism of Action Cannabinoid receptor CB2 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Neuropathic pain
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Neuropathic-pain in Italy
- 05 Jul 2016 Research programme: cannabinoid receptor CB2 modulatorsagonists - C4T SCarl is available for licensing - http://www.c4t.it/public/files/C4T_CB2_agonists.pdf
- 05 Jul 2016 Preclinical trials in Neuropathic pain in Italy (unspecified route)